Personalized Evidence-based Medicine Improves Outcomes of Anticoagulation Therapy in Patients With Atrial Fibrillation
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 4,200
- 试验地点
- 1
- 主要终点
- The percentage of guideline-based and personalized EBM recommendations
研究概览
简要总结
A retrospective analysis
详细描述
4200 EMR of patients at high risk for stroke with 1-year follow-up will be enrolled in the current study and analyzed by clinical decision support systems (CDSS MedicBK) utilizing a core laboratory.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •EMR only if an ECG diagnosis (12-lead ECG, 24-h Holter, or other electrocardiographic documentation) confirming AF was made in patients at high risk for stroke by CHA2DS2-VASc (≥2 in men and ≥3 in women).
排除标准
- 未提供
研究组 & 干预措施
CDSS (MedicBK) Analysis
干预措施: anticoagulation treatment (Drug)
Core Laboratory Analysis
干预措施: anticoagulation treatment (Drug)
结局指标
主要结局
The percentage of guideline-based and personalized EBM recommendations
时间窗: 1-year
The percentage of guideline-based and personalized EBM recommendations acted on by clinicians for anticoagulant therapy in patients with AF. All discrepancies between routine and CDSS-recommended treatment resulting in frame of guideline-based therapy and personalized EBM therapy will be adjudicated by core laboratory.
次要结局
- Predictors(1-year)
- 1-year FU outcomes(1-year)
- Quantify the performance of the CDSS (MedicBK) algorithm(1-year)
研究者
Evgeny Pookushalov
Director for research and development
Center of Personalized Medicine, Pirogova